SSR 504734Alternative Names: SSR-504734
Latest Information Update: 17 Mar 2009
At a glance
- Originator sanofi-aventis
- Class Antipsychotics
- Mechanism of Action Glycine transporter 1 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Schizophrenia